SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dipna Pharmachem Ltd (543594)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543594 NSE: Trading | Small Cap | Dipna Pharma. Share Price

₹7.47 0.29 (4.04%)

As on 05-Jun'26 10:57

Dipna Pharmachem Ltd (543594)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543594 NSE: Trading | Small Cap | Dipna Pharma. Share Price

₹7.47 0.29 (4.04%)

As on 05-Jun'26 10:57

Key Metrics
Valuation Multiples
Market Cap
₹19 Cr.
Current Price
₹7.5
52-Week Low / High
₹7 / 26
TTM EPS
₹0.4
TTM Sales
₹125 Cr.
Book Value per Share
₹15.8
P/E Ratio
19.38
Lower than its 5-year historical median
Industry PE
36
Price to Book (P/B)
0.46
Lower than its 5-year historical median
Price to Sales (P/S)
0.15
Lower than its 5-year historical median
EV/EBITDA
9.08
Lower than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
2.56%
Outperforms industry median
Return on Capital Employed (ROCE)
6.95%
Outperforms industry median
Return on Assets (ROA)
0.73%
Operating Profit Margin
3.1%
Net Profit Margin
0.78%
Gross Profit Margin
1.2%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-23.99%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
12%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
-11.01%
Asset Quality
Promoter Holding
9.13%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹15 Cr.
Equity
₹26.3 Cr.
Face Value
₹10
All Time Low / High
₹6.40 / 27.61

Dipna Pharmachem stock performance

Key Ratios
mw4me loader

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Dipna Pharmachem Ltd a good quality company?
Dipna Pharmachem Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Dipna Pharmachem Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Dipna Pharmachem Ltd vs industry peers?
Dipna Pharmachem Ltd revenue CAGR is 32.54%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Dipna Pharmachem Ltd?
Promoters hold 9.13% of the Dipna Pharmachem Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Dipna Pharmachem Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of -15.17% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Dipna Pharmachem Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 7.2%8%5.4%3.5%18.2%9.2%7.2%7%-
Value Creation
Index
-0.5-0.4-0.6-0.80.3-0.4-0.5-0.5-

Growth Parameters

Sales 16.620.230.53172.899.9164125125
Sales YoY Gr.-21.9%51.3%1.5%134.7%37.3%64.5%-24%-
Adj EPS 3.554.41.257.10.60.50.40.4
YoY Gr.-43.4%-12.8%-72.9%4736.4%-98.9%-28.6%-8.9%-
BVPS (₹) 22.323.926.8288516.715.61615.8
Adj Net
Profit
0.10.10.101.20.91.111
Cash Flow from Ops. 00-3.1-2.42.8-21-5.4-9.2-
Debt/CF from Ops. 00-3.1-5.13.6-0.8-3.6-1.9-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NA32.5%19.7%-24%
Adj EPS NA-37.7%-80.7%-8.9%
BVPSNA-9.8%-42.7%2.6%
Share Price - - -18.8% -67.1%

Key Financial Parameters

Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
15.621.617.24.310173.52.62.3
Op. Profit
Mgn %
2.42.91.61.33.12.42.13.1NAN
Net Profit
Mgn %
0.40.50.30.11.60.90.70.80.8
Debt to
Equity
11.212.317.521.75.90.70.50.5-
Working Cap
Days
02231922521521972123670
Cash Conv.
Cycle
07483115474915-410

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales16.5620.1830.543172.7699.93164.34124.92
Operating Expenses + 16.1719.7030.0930.6070.5097.53160.83121
Manufacturing Costs1.460.440.080.060.410.130.090.10
Material Costs14.1718.5328.9429.5868.5695.49157.91113.73
Employee Cost 0.260.350.380.410.620.450.450.42
Other Costs 0.280.370.680.550.911.462.386.76
Operating Profit 0.380.480.450.402.262.403.503.92
Operating Profit Margin (%) 2.3%2.4%1.5%1.3%3.1%2.4%2.1%3.1%
Other Income + 0.010.010.010.020.010.0100.01
Exceptional Items 00000000
Interest 0.330.430.390.350.691.012.072.50
Depreciation 00.010.010.010.010.010.020.01
Profit Before Tax 0.070.060.060.061.571.381.421.42
Tax 0.010.0200.030.410.470.330.45
Profit After Tax 0.060.030.060.021.170.911.090.97
PAT Margin (%) 0.4%0.2%0.2%0.1%1.6%0.9%0.7%0.8%
Adjusted EPS (₹)3.01.62.91.257.10.60.50.4
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%

Valuation of Dipna Pharma. - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 0.460.490.550.571.7424.3637.5238.49
Share Capital 0.040.040.040.040.0411.9724.0524.05
Reserves 0.420.450.510.541.7012.3913.4714.45
Debt +5.106.019.5712.4310.1915.9119.4517.22
Long Term Debt003.363.685.8010.9712.558.89
Short Term Debt5.106.016.218.744.394.946.908.33
Minority Interest00000000
Trade Payables5.507.538.3111.7823.0336.2874.5475.73
Others Liabilities 0.030.030.010.021.271.011.400.94
Total Liabilities 11.0814.0618.4424.7936.2377.56132.90132.38

Fixed Assets

Net Fixed Assets +0.010.050.040.040.040.040.040.05
Gross Block0.010.070.070.070.080.090.110.13
Accumulated Depreciation0.010.020.030.030.040.050.070.08
CWIP 00000000
Investments 00000000
Inventories4.353.345.557.206.3018.9437.3827.43
Trade Receivables68.8511.2014.9526.9728.5330.9446.28
Cash Equivalents 0.300.120.180.250.215.6913.880.43
Others Assets 0.441.711.472.362.7024.3550.6758.19
Total Assets 11.0814.0618.4424.7936.2377.56132.90132.38

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 00-3.12-2.432.81-20.98-5.42-9.19
PBT 000.060.061.571.381.421.42
Adjustment 000.390.350.610.972.012.03
Changes in Working Capital 00-3.57-2.821.03-22.86-8.51-12.2
Tax Paid 00-0-0.02-0.41-0.47-0.34-0.45
Cash Flow From Investing Activity + 000.010-0.01-0.01-0.01-0.02
Capex 00-0-0.01-0.01-0.01-0.01-0.02
Net Investments 00000000
Others 000.010.010000
Cash Flow From Financing Activity + 003.172.50-2.8426.4713.62-4.24
Net Proceeds from Shares 0000021.7112.080
Net Proceeds from Borrowing 000.510.32-0.3600-3.66
Interest Paid 00-0.39-0.35-0.61-0.96-2-2.02
Dividend Paid 00000000
Others 003.052.53-1.885.723.541.43
Net Cash Flow 000.060.08-0.045.488.19-13.45

Financial Ratio

PARTICULARSMar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)13.246.7811.394.32101.026.993.512.56
ROCE (%)7.167.985.423.5418.169.177.186.95
Asset Turnover Ratio1.491.611.881.432.381.761.560.94
PAT to CFO Conversion(x)00-52-121.52.4-23.05-4.97-9.47
Working Capital Days
Receivable Days132.30134.30119.80153.90105.20101.4066112.80
Inventory Days95.9069.5053.1075.1033.9046.1062.6094.70
Payable Days141.60128.3099.9012492.70113.40128.10241.10

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Dipna Pharmachem Ltd FAQs

The current trading price of Dipna Pharma. on 05-Jun-2026 10:57 is ₹7.47.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Jun-2026 the market cap of Dipna Pharma. stood at ₹18.88 Cr

The latest P/E ratio of Dipna Pharma. as of 04-Jun-2026 is 19.38.

The latest P/B ratio of Dipna Pharma. as of 04-Jun-2026 is 0.46.

The 52-week high of Dipna Pharma. is ₹25.66 and the 52-week low is ₹6.66.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Dipna Pharma. is ₹125 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Dipna Pharmachem Ltd is a below average quality company.

The key valuation ratios of Dipna Pharmachem Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Dipna Pharmachem Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Dipna Pharmachem Ltd

The company was originally incorporated as “Dipan Pharmachem Private Limited” under the provisions of Companies Act, 1956 vide Certificate of Incorporation dated July 19, 2011 bearing Corporate Identification Number issued by the Registrar of Companies, Gujarat, Dadra and Nagar Havelli. Subsequently, the name of company was changed to “Dipna Pharmachem Private Limited” and a fresh certificate of incorporation was issued by Registrar of Companies, Gujarat, Dadra and Nagar Havelli on March 29, 2012. After that, the Company was converted from Private limited to Public Limited company pursuant to a special resolution passed by shareholders at the EGM held on May 13, 2022 and consequently the name of Company was changed as “Dipna Pharmachem Limited” and a fresh certificate of incorporation was issued by the Registrar of Companies, Ahmedabad dated May 25, 2022.

The company is engaged in the trading and distribution of wide range of pharmaceutical raw material which is also known as APIs (Active Pharmaceutical Ingredients), Excipient and chemical formulation products. Presently its product portfolio comprises of 61 AIPs and AIPs intermediates such as Cephalosporins, Cardiovasculars, Anti - Bactaria, Quinolones, Veterinary, Anti - Virus, Anti - Inflammatory, Neuropsychiatry, Steroid Hormone, other etc. Being a trading and distribution company, it has pan India market for its products. The company had also started the selling of chemicals on commission basis. In the financial year 2022, the company had earned commission income of Rs 127.50 lakh. The company is doing trading in Ahmedabad and surrounding area of Ahmedabad.

Business area of the company

Dipna Pharmachem is a trader, importer, and exporter in industrial Chemical and Pharmaceutical Raw materials, APIs, solvents, and Formulation since 2011. The company’s huge portfolio includes expertise for marketing and sourcing of industrial Chemical and Pharmaceutical Raw materials, APIs, solvents, and Formulation and intermediates, assistance in setting up contract manufacturing compliance for regulated, semi-regulated pharmaceutical companies with all the global benchmark parameters of leading certificates like WHO-GMP.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×